HALO · Halozyme Therapeutics Inc
United States · RS rating 98 · As of 2026-10-14
| Price | 116.82 USD |
|---|---|
| 1-day change | +6.6% |
| RS rating (overall / 1M / 3M / 12M) | 98 / 93 / 96 / 94 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 48 / 60 / 47 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -183.9% |
| Sales growth Q/Q | +27.5% |
| Distance from 52-week high | +0.0% |
| Market cap (USD) | $7.9B |